Jersey Oil and Gas investors to watch keenly as UK Govt's fiscal consultations proceed
Details will need to be fleshed out, but the UK government has heard the concerns of the North Sea industry, that's what Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) boss Andrew Benitz told investors as Westminster began a round of fiscal consultations. AIM-quoted Jersey and partner Dana Petroleum are poised to develop the Buchan project, which promises additional domestic gas supplies, though the project timeline is in the air amidst uncertainties over the tax regime for the North Sea.
KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said that its secured lenders have increased project financing facilities to $240 million, from $190 million.
Polarean Imaging inks partnership with US outpatient medical imaging firm
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) is teaming up with SimonMed Imaging, one of America's largest outpatient medical imaging providers. It will see the AIM-quoted firm's Xenon MRI platform delivered across the SimonMed network – starting with a site in Scottsdale, Arizona, later this year.
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?
AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Deltex Medical shares plunge 50% on proposed AIM cancellation and CEO resignation
Shares in Deltex Medical Group plc (AIM:DEMG) (AIM: DEMG) fell 50% following the announcement of a proposed delisting from AIM and leadership changes. The company attributed its decision to delist to the high costs of maintaining its AIM listing, estimated at £200,000 annually, representing 10% of its unaudited 2024 revenues of £2.1 million.
Orosur Mining Inc Announces Exercise of Warrants
Orosur Mining Inc Exercise of Warrants, Issue of Shares and Total Voting Rights LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM/TSXV:OMI), a minerals explorer and developer with projects in Colombia, Argentina and Nigeria, advises that, following an exercise of 179,856 warrants at an exercise price of US$0.0494 (approximately 3.984p) each, the Company will, issue 179,856 new common shares of no par value each ("Common Shares") for a total consideration of US$8,885. Application will be made for the 179,856 Common Shares, which rank pari passu with the existing Common Shares in issue, to be admitted to trading on AIM ("Admission").
Eden Research's regulatory wins keep coming at breakneck pace
Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't happen in a bubble. Rather, it's merely the latest in a long line of regulatory wins secured by the company in a couple of short years.
SDX Energy shares plunge on London delisting plan
SDX Energy PLC (AIM:SDX, OTC:SDXEF) shares plunged around 60% in value on Friday as it announced it intends to exit the London Stock Exchange, delisting from AIM to take up private company status. It is a cost-cutting move for the company which previously sold its primary asset, a gas field in Egypt, to retain gas-producing assets in Morocco, and last month secured a $4.5 million refinancing of a convertible loan.
Shield Therapeutics ‘on track for 2024' - analyst
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed pharma group, said Stifel analysts. “This, along with the business looking to lower its cost base by circa 10%, will help strengthen the balance sheet and support achieving cash flow breakeven by 2025 year-end,” they stated, adding that the company is “on track for 2024”.
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Pantheon Resources aims to boost profile with US investors
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has hired an American investor relations firm as it seeks to woo US investors, ahead of the next wave of progress at the AIM-quoted firm's Alaskan oil and gas assets. It has appointed MZ Group to lead its investor relations efforts in the US.
Inheritance tax raid no death kell for AIM market, says London Stock Exchange exec
The potential removal of inheritance tax relief on AIM-listed shares in the upcoming UK Budget has sparked concerns among investors, with many viewing the change as "painful" and "unnecessary". However, Marcus Stuttard, head of AIM and UK primary markets at the London Stock Exchange, doesn't expect Chancellor Rachel Reeve's impending tax raid to be a death knell for the junior market.
